All eyes on Microsoft and Pfizer

Microsoft

Most analysts foresee that the software giant has to exceed market forecasts this time. And if it really does, Microsoft will skyrocket. The Wall Street consensus is for revenue of $35.7 billion with profits of $1.54 a share. Last time the company revealed revenue of $38 billion with profits of $1.46, beating estimates of $36.4 billion and $1.38, relatively. Microsoft has managed not only to withstand the devastating coronavirus, but also to outperform! Its’ different products such as Azure, Office365, PC – all benefit from the stay-at-home regime as lots of companies have been forced to work remotely. Elsewhere, the soon release of the new Xbox added optimism. No doubt that this time the results will be better than expected. Stifel bank ungraded its price target to $245.00. Get ready to use this great opportunity on October 27 at 23:30 MT time!

Microsoft is currently at the 50.0% Fibonacci retracement level. It’s great that there is more room for the stock to rise firstly to the 78.6% Fibonacci level of $225.00 and then to $233.00. Moreover, it has strong supports of the 50-day moving average of $212.00 just underneath, that it’s unlikely to cross. Awesome chance to gain some profit!

Pfizer

If it’s all clear for Microsoft, Pfizer’s position is not so strong. Pfizer is working in a collaboration with a young, but highly-potential company BioNTech. Their vaccine candidate is one of the few frontrunners in the race nowadays. As you may remember, Johnson & Johnson and AstraZeneca have already left the competition because of the patients’ negative reactions. So, who knows, maybe Pfizer will save the world from the virus. If they succeed, they will receive $1.95 billion from the US government to supply 100 million doses. Of course, the company depends not only on the success of the vaccine, but it also has many other products. Notably, it’s one of the deepest pipelines in the biopharmaceutical industry. Follow the earnings report on October 27 at 16:00 MT time and catch the market movement!

Pfizer is trading inside of the triangle pattern. It has approached the intersection of the trendlines, so the earnings report may become the decisive moment for the stock. If earnings are better than expected, Pfizer may jump to $39.00 and then to $40.50. Otherwise, the move below the 50-day moving average of $37.00 will drive the price to the 200-day MA at $36.25. Follow the releases and join the flow!

TRADE NOW

What should you do for trading stocks?

Trading stocks with FBS is easy. Follow the simple steps described below.

FBS Analyst Team